Mette Kirstine Agger
CIK: 0001722234
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (5 total)
- Jun 25, 2026LXEO
Lexeo Therapeutics, Inc.
Award(A)DirectStock Option (right to buy)
35K shares- - Oct 7, 2025SCPH
scPharmaceuticals Inc.
Disposition(D)DirectStock Option (Right to Buy)
30K shares- - Oct 7, 2025SCPH
scPharmaceuticals Inc.
Disposition(D)DirectStock Option (Right to Buy)
19.8K shares- - Jun 26, 2025LXEO
Lexeo Therapeutics, Inc.
Award(A)DirectStock Option (right to buy)
25K shares- - Jun 3, 2025SCPH
scPharmaceuticals Inc.
Award(A)DirectStock Option (Right to Buy)
30K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 25, 2026 |  LXEO Lexeo Therapeutics, Inc. | Award(A) Stock Option (right to buy) | 35,000 | - | - | Direct |
| Oct 7, 2025 |  SCPH scPharmaceuticals Inc. | Disposition(D) Stock Option (Right to Buy) | 30,000 | - | - | Direct |
| Oct 7, 2025 | SCPH scPharmaceuticals Inc. | Disposition(D) Stock Option (Right to Buy) | 19,750 | - | - | Direct |
| Jun 26, 2025 | LXEO Lexeo Therapeutics, Inc. | Award(A) Stock Option (right to buy) | 25,000 | - | - | Direct |
| Jun 3, 2025 | SCPH scPharmaceuticals Inc. | Award(A) Stock Option (Right to Buy) | 30,000 | - | - | Direct |
1-5 of 5 transactions
About Agger Mette Kirstine
Agger Mette Kirstine (SEC CIK 0001722234) files insider reports with the SEC as Director of Lexeo Therapeutics, Inc. (LXEO) and Director of scPharmaceuticals Inc. (SCPH).
Signal8 holds 4 ownership filings by Agger Mette Kirstine, all Form 4s, filed between Jun 5, 2025 and Jun 29, 2026. Those filings report 5 transactions, from Jun 3, 2025 to Jun 25, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Agger Mette Kirstine's filings is in NEW YORK, NY.
Recent filings by Agger Mette Kirstine
- Jun 25, 2026: Grant or award of LXEO derivative securities (Form 4, code A).
- Oct 7, 2025: Disposition to issuer transactions of SCPH derivative securities (2 lines, Form 4, code D).
- Jun 26, 2025: Grant or award of LXEO derivative securities (Form 4, code A).
- Jun 3, 2025: Grant or award of SCPH derivative securities (Form 4, code A).
Other insiders filing for Lexeo Therapeutics, Inc. (LXEO)
- Tamayo Louis Edward, Chief Financial Officer
- Bhalla Narinder Pal, Chief Medical Officer
- Otero Jose Manuel, Chief Operating Officer
- Townsend Richard Nolan, Chief Executive Officer
- Altschuler Steven, Director
- COOPERSTONE BRENDA, Director